Treatment Options for Insomnia

Ramakrishnan K, MD
Scheld DC, MD, MPH
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Correspondence to: Prof K Ramakrishnan, e-mail: kramakrishnan@ouhsc.edu

Abstract

The frequency of sleep disruption and the degree to which insomnia significantly affects daytime function determine the need for evaluation and treatment. Physicians may initiate treatment of insomnia at an initial visit; for patients with a clear acute stressor such as grief, no further evaluation may be indicated. However, if insomnia is severe or long-lasting, a thorough evaluation to uncover coexisting medical, neurologic, or psychiatric illness is warranted. Treatment should begin with non-pharmacologic therapy, addressing sleep hygiene issues and exercise. There is good evidence supporting the effectiveness of cognitive behavior therapy. Exercise improves sleep as effectively as benzodiazepines in some studies and, given its other health benefits, is recommended for patients with insomnia. Hypnotherapy generally should be prescribed for short periods only, with the frequency and duration of use customized to each patient's circumstances. Routine use of over-the-counter drugs containing antihistamines should be discouraged. Alcohol has the potential for abuse and should not be used as a sleep aid. Opiates are valuable in pain-associated insomnia. Benzodiazepines are most useful for short-term treatment; however, long-term use may lead to adverse effects and withdrawal phenomena. The better safety profile of the newer-generation non-benzodiazepines (i.e., zolpidem, zaleplon, eszopiclone, and ramelteon) makes them better first-line choices for long-term treatment of chronic insomnia. Copyright © 2007 American Academy of Family Physicians.

SA Fam Pract 2007;49(8): 34-41

Introduction

The American Academy of Sleep Medicine defines insomnia as unsatisfactory sleep that impacts daytime functioning. More than one third of adults report some degree of insomnia within any given year, and 2 to 6 percent use medications to aid sleep. Insomnia is associated with increased morbidity and mortality caused by cardiovascular disease and psychiatric disorders and has other major public health and social consequences, such as accidents and absenteeism. Risk factors for chronic insomnia include increasing age, female sex, psychiatric illness, medical comorbidities, impaired social relationships, lower socioeconomic status, separation from a spouse or partner, and unemployment.

Evaluation

Criteria for the diagnosis of insomnia are provided in Table 1. Although there are several classification systems, it is practical to divide insomnia into two categories by duration: acute (i.e., less than 30 days) and chronic (i.e., 30 days or longer). If insomnia is associated with another condition, it is designated as co-morbid insomnia (Table 2). Only about 15 to 20 percent of patients with chronic insomnia have no other associated diagnosis (primary insomnia).

<table>
<thead>
<tr>
<th>SORT: KEY RECOMMENDATIONS FOR PRACTICE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical recommendation</strong></td>
</tr>
<tr>
<td>Exercise, cognitive behavior therapy, and relaxation therapy are recommended as effective, non-pharmacologic treatments for chronic insomnia.</td>
</tr>
<tr>
<td>Melatonin is effective in patients with circadian rhythm sleep disorders and is safe when used in the short term.</td>
</tr>
<tr>
<td>Benzodiazepines are effective for treating chronic insomnia but have significant adverse effects and the risk of dependency.</td>
</tr>
<tr>
<td>Non-benzodiazepines (e.g., eszopiclone, zaleplon, zolpidem) are effective treatments for chronic insomnia and, based on indirect comparisons, appear to have fewer adverse effects than benzodiazepines.</td>
</tr>
</tbody>
</table>

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 483 or http://www.aapt.org/sort/evidenceRating.xml.

Table 1: Criteria for the Diagnosis of Insomnia

At least one of the following complaints:
- Difficulty initiating and/or maintaining sleep; sleep that is poor in quality; trouble sleeping despite adequate opportunity and circumstances for sleep; waking up too early
- At least one of the following types of daytime impairment related to sleep difficulty: Attention, concentration, or memory impairment; concerns or worries about sleep; daytime sleepiness; errors or accidents at work or while driving; fatigue or malaise; gastrointestinal symptoms; lack of motivation; mood disturbance or irritability; social or vocational dysfunction or poor school performance; tension headaches

Information from reference 5.

The frequency of sleep disruption and the degree to which insomnia significantly affects daytime function (e.g., quality of life, work limitations, mood, social life) are probably the most important determinants of the need for evaluation and treatment. If the initial evaluation identifies an acute stressor such as grief or noise, no further evaluation is indicated and treatment can be initiated. A more comprehensive evaluation should be pursued with nonresponders or if a comorbid condition is present or suspected.
The evaluation of chronic insomnia should involve a detailed history and examination to detect any coexisting medical or psychiatric illness and may include an interview with a partner or caregiver. Evaluation should include an assessment of sleep dysfunction and a sleep diary (Table 3). Following this evaluation, the need for further testing or pharmacotherapy can be determined.

Treatment Overview
Ideally, treatment for insomnia would improve sleep quantity and quality, improve daytime function (greater alertness and concentration), and cause minimal adverse drug effects. An approach to the evaluation and treatment of the patient with insomnia is shown in Figure 1. Most experts recommend starting with nonpharmacologic therapy (Table 4).

Good evidence supports a benefit for relaxation therapy and cognitive-behaviour therapy (CBT) that may be sustained over six to 24 months. Exercise improves sleep as effectively as benzodiazepines in some studies and, given its other health benefits, is recommended for patients with insomnia. Behavioural and cognitive interventions have minimal risk of adverse effects, but disadvantages include high initial cost, lack of insurance coverage, few trained therapists, and decreased effectiveness in older adults.

Pharmacologic Therapy
Hypnotics are recommended when immediate symptom response is desired, when insomnia produces serious impairment, when nonpharmacologic measures do not produce the desired improvement, or when insomnia persists after treatment of an underlying medical condition. Table 5 outlines prescribing guidelines for hypnotics.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognitive behaviour therapy</td>
<td>Helps change incorrect beliefs and attitudes about sleep (e.g., unrealistic expectations, misconceptions, amplifying consequences of sleeplessness); techniques include reattribution training (i.e., goal setting and planning coping responses), decatastrophizing (aimed at balancing anxious automatic thoughts), reappraisal, and attention shifting</td>
</tr>
<tr>
<td>Exercise</td>
<td>Moderate-intensity exercise (should not occur just before bedtime)</td>
</tr>
<tr>
<td>Relaxation therapy</td>
<td>Tensing and relaxing different muscle groups; biofeedback or imagery (visual and auditory feedback) to reduce somatic arousal; medication hypnotics</td>
</tr>
<tr>
<td>Sleep restriction (paradoxical intention therapy)</td>
<td>Uses a paradoxical approach in which the patient spends less time in bed (by associating time spent in bed with time spent sleeping)</td>
</tr>
<tr>
<td>Polysomnography, multiple sleep latency testing</td>
<td>Bedtimes are then increased or decreased progressively depending on improvement or deterioration of sleep quality and duration</td>
</tr>
<tr>
<td>Actigraphy</td>
<td>This state of minimal sleep deprivation eventually leads to more efficient sleep</td>
</tr>
<tr>
<td>Avoid bright lights (including television); noise and temperature extremes; and large meals, caffeine, tobacco, and alcohol at night</td>
<td>Minimize evening fluid intake; leave the bedroom if unable to fall asleep within 20 minutes; limit use of the bedroom to sleep and intimacy</td>
</tr>
<tr>
<td>Temporal control measures</td>
<td>Consistent time of wakening; minimal daytime napping</td>
</tr>
</tbody>
</table>

Table 4: Non-pharmacologic treatments for insomnia

Table 3: Evaluation of Insomnia

Selected causes of acute insomnia (< 30 days)*
- Situational stress (e.g., occupational, interpersonal, financial, academic, medical)
- Environmental stressors (e.g., noise)
- Death or illness of a loved one

Selected causes of chronic insomnia (≥ 30 days)
- Medical disorders
  - Arthritis, cancer, chronic pain, congestive heart failure, COPD, end-stage renal disease, gastroesophageal reflux disease, HIV/AIDS, hypothyroidism, nocturia caused by prostatic hypertrophy, stroke
- Medications
  - Antihistaminics: antihistamines (SSRIs, bupropion [Wellbutrin®], MAOIs; anticholinergics: anticholinergic antihistamines)
- Relaxation therapy
- Sleep diary
- Sleep restriction (paradoxical intention therapy)
- Polysomnography, multiple sleep latency testing
- Actigraphy
- Avoid bright lights (including television); noise and temperature extremes; and large meals, caffeine, tobacco, and alcohol at night
- Minimize evening fluid intake; leave the bedroom if unable to fall asleep within 20 minutes; limit use of the bedroom to sleep and intimacy

Table 3: Evaluation of Insomnia

- History and examination: Helps detect any coexisting medical or psychiatric illness
- Sleep history must span the entire day and should include an interview with the partner or caregiver
- Interview partner or caregiver about patient's sleep habits, daytime functioning, substance use (e.g., alcohol, tobacco, caffeine), snoring, apnoea, and unusual limb movement
- Take medication history; physical examination should include neurological examination, Mini-Mental State Examination
- Sleep diary: A two-week sleep diary should record information on bedtime, rising time, daytime naps, sleep-onset latency, number of night time wakenings, total sleep time, and the patient's mood on arousal
- Questions should include daytime symptoms such as somnolence and frequency of napping
- Polygraphy, multiple sleep latency testing
- Useful if sleep apnoea or periodic limb movement disorder is suspected
- Use when behavioural and psychopharmacologic treatments are unsuccessful
- Actigraphy: An activity monitor or motion detector, typically worn on the wrist, records movement; the absence of movement for a given continuous period is consistent with sleep
- Useful in evaluating sleep patterns in patients with insomnia, analyzing the beneficial or detrimental effects of measures, diagnosing circadian rhythm disorders, and evaluating sleep in patients unable to tolerate polysomnography
- Neuroimaging: Use if a structural lesion (e.g., mass lesion, arteriovenous malformation) is suspected on history and examination
- Information from references 3, 8, and 10.

Antihistamines
Nearly 25 percent of patients with insomnia use over-the-counter (OTC) sleep aids, and 5 percent use them at least several nights a week. Routine use of OTC antihistamines such as diphenhydramine and doxylamine should be discouraged because they are only minimally effective in inducing sleep, may reduce sleep quality, and can cause residual drowsiness.
**Evaluation and Treatment of Insomnia**

Figure 1: Approach to the evaluation and treatment of the patient with insomnia. (BPH = benign prostatic hypertrophy; CHF = congestive heart failure; MSLT = multiple sleep latency test.)

**HERBAL AND DIETARY SUPPLEMENTS**

Many herbs and dietary supplements (e.g., valerian root, melatonin, lavender, passionflower, kava, St. John’s wort, glutamine, niacin, and L-tryptophan) have been promoted as sleep aids. There is insufficient evidence of benefit except for melatonin and valerian. Melatonin, a hormone produced by the pineal gland that is involved in sleep regulation, improves insomnia caused by circadian schedule changes (e.g., jet lag, shift work). Melatonin has been approved by the U.S. Food and Drug Administration (FDA) to treat circadian rhythm sleep disorder in blind children and adults, but it is unregulated and preparations vary greatly in strength. At higher doses, it causes sleep disruption, daytime fatigue, headache, dizziness, and irritability (Table 6). Little information is available about the safety of long-term use.

Valerian root causes central sedation by inhibiting the breakdown of gamma-aminobutyric acid (GABA) or its metabolites. There is minimal evidence for its effectiveness in treating insomnia. Residual daytime sedation and, rarely, hepatotoxicity are adverse effects. Preparations are unregulated by the FDA and may vary in valerian content.

**ALCOHOL**

At least 10 percent of young adults use OTC medications or alcohol in any given year to improve sleep. Alcohol, a central nervous system (CNS) stimulant and depressant, acts directly on GABA-gated channels reducing sleep-onset latency, but it also increases wakefulness after sleep onset and suppresses rapid eye movement (REM) sleep. Alcohol has the potential for abuse and should not be used as a sleep aid.

**BARBITURATES, OPIATES, AND ANTIDEPRESSANTS**

Barbiturates function as GABA<sub>B</sub> brain receptor agonists, decreasing sleep-onset latency and suppressing REM sleep. They are effective in short-term insomnia (i.e., up to two weeks) but lose the ability to induce and maintain sleep beyond this period. Longer-term use (i.e., more than two weeks) is associated with tolerance, physical and psychological dependence, and increased adverse effects (i.e., agitation, confusion, nightmares, hallucinations, lethargy, and hangover). Barbiturates should rarely be used as sleep aids.

Opiates fragment sleep and decrease REM and stage 2 sleep. By producing analgesia and sedation, opiates may be appropriate in carefully selected patients with pain-associated insomnia. Some antidepressants (e.g., amitriptyline, doxepin, trazodone, mirtazapine) produce sedation by blocking acetylcholine, norepinephrine, and serotonin presynaptic receptors. Compared with placebo, antidepressants decrease sleep latency.

**Table 5: Guidelines for prescribing hypnotics**

1. Initiate hypnotic use with identifying and addressing specific behaviors, circumstances, and underlying disorders contributing to insomnia.
2. Prescribe the lowest effective dose of the hypnotic.
3. Prescribe hypnotics for short durations (two to four weeks) and intermittently (duration based on patient's return to an acceptable sleep cycle).
4. Avoid hypnotic use or exercise caution if patient has a history of substance abuse, myasthenia gravis, respiratory impairment, or acute cerebrovascular accident.
5. Watch for requests for escalating doses or resistance to tapering or discontinuing hypnotic.
6. Hypnotics should be discontinued gradually (i.e., tapered); physician should be alert for adverse effects (especially rebound insomnia) and withdrawal phenomena.

Information from reference 18.
sleep-onset latency and wakefulness after sleep onset (Table 7). They also increase total sleep time, sleep efficiency, and sleep quality but suppress REM sleep. Antidepressants are an effective treatment option in patients with insomnia and coexisting depression. Trazodone is the most commonly prescribed sleep aid, but there is insufficient evidence to support its use in the absence of depression.

**Benzodiazepine Hypnotics**

Benzodiazepines bind to GABA and GABA receptors, acting as antagonists. They have less risk of overdose and abuse potential than barbiturates. Benzodiazepines increase sleep time and improve sleep quality by reducing sleep-onset latency and wakefulness after sleep onset and by increasing sleep efficiency (Table 7). However, they also potentiate CNS depression with alcohol or other sedatives. Benzodiazepines that have been approved by the FDA for treating chronic insomnia include estazolam, flurazepam, temazepam, quazepam, and triazolam. Rapidly acting drugs with shorter half-lives (i.e., estazolam, triazolam, and temazepam) are preferred. Temazepam has a slower onset of action and is less effective for initiating sleep. Flurazepam and quazepam have half-lives longer than 24 hours.

Because tolerance and dependence occur with prolonged use, benzodiazepines are most useful for the short-term treatment of insomnia. Using benzodiazepines for more than four weeks increases the likelihood of dependence (defined as a compulsive or chronic need) and withdrawal phenomena (defined as a symptom complex that develops following discontinuation). An estimated 10 to 30 percent of chronic benzodiazepine users develop dependence, and 50 percent suffer withdrawal. Dependence is more likely with daily use for more than four months, with higher doses, in older patients, in patients with previous hypnotic or alcohol dependence, and when using high-potency, shorter-acting benzodiazepines.

Benzodiazepine withdrawal may cause anxiety, depression, nausea, perceptual changes, rebound insomnia, intense dreams, nightmares, and poor memory consolidation. Withdrawal symptoms may develop within a few hours of discontinuing a short-acting benzodiazepine, or up to three weeks for a long-acting benzodiazepine.

### Table 6: Pharmacologic Treatment of Insomnia

<table>
<thead>
<tr>
<th>Drug</th>
<th>Daily dosage (mg)</th>
<th>Peak action (hours)</th>
<th>Half-life (hours)</th>
<th>Cost, 30 days (generic)</th>
<th>Adverse effects and considerations</th>
<th>FDA approved?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-benzodiazepines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zolpidem</td>
<td>5 to 10</td>
<td>0.5</td>
<td>2 to 3</td>
<td>$102</td>
<td>Abdominal pain, rebound insomnia; controlled-release formulation; better for sleep maintenance; FDA pregnancy risk category B (not controlled-release formulation); CYP3A4-dependent metabolism</td>
<td>Yes</td>
</tr>
<tr>
<td>Zaleplon</td>
<td>5 to 10</td>
<td>0.5</td>
<td>1</td>
<td>$103</td>
<td>Better for sleep maintenance; altered color perception; CYP3A4-dependent metabolism</td>
<td>Yes</td>
</tr>
<tr>
<td>Eszopiclone</td>
<td>2 to 3</td>
<td>1</td>
<td>4 to 6</td>
<td>$121</td>
<td>Unpleasant taste (8 to 24 percent); amnesia, hallucinations, worsening depression; CYP3A4-dependent metabolism</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Melatonin receptor agonist</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramelteon</td>
<td>8 to 16</td>
<td>0.3</td>
<td>2 to 5</td>
<td>$81</td>
<td>Suicidal ideation, dizziness, headache, increased prolactin levels; contraindicated with fluvoxamine and liver failure; CYP3A4-, CYP1A2-, and CYP2C9-dependent metabolism</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Antihistamines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphenhydramine</td>
<td>25 to 50</td>
<td>1 to 3</td>
<td>8</td>
<td>$5 (1 to 3)</td>
<td>Anticholinergic, CNS depression/stimulation; FDA pregnancy risk category B</td>
<td>Yes</td>
</tr>
<tr>
<td>Doxylamine</td>
<td>12.5 to 25</td>
<td>2 to 3</td>
<td>10</td>
<td>$8</td>
<td>Anticholinergic, CNS depression/stimulation; FDA pregnancy risk category A</td>
<td>Yes</td>
</tr>
<tr>
<td>Hydroxyzine</td>
<td>25 to 100</td>
<td>2</td>
<td>3 to 7</td>
<td>$37 (9 to 21)</td>
<td>Anticholinergic, CNS depression/stimulation</td>
<td>No</td>
</tr>
<tr>
<td><strong>Antidepressants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>25 to 100</td>
<td>2 to 4</td>
<td>17 to 40</td>
<td>$21 (2 to 4)</td>
<td>Anticholinergic, morning sedation, daytime somnolence, accidents, cardiac toxicity, sexual dysfunction, serotonin syndrome (SSRI interaction), exacerbates restless legs syn.</td>
<td>No</td>
</tr>
<tr>
<td>Trazodone</td>
<td>50 to 150</td>
<td>0.5 to 2</td>
<td>8</td>
<td>$68 (9 to 13)</td>
<td>Same as above</td>
<td>No</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>----------</td>
<td>---</td>
<td>---------------</td>
<td>---------------</td>
<td>----</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>15 to 45</td>
<td>1.2 to 1.6</td>
<td>20 to 40</td>
<td>$104 (81 to 83)</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

**Benzodiazepines**

| Trazolam | 0.125 to 0.5 | 1 to 2 | 1.5 to 5 | $42 (18 to 21) | Rapid onset, short half-life; anterograde amnesia, rapid eye movement sleep rebound; CYP3A4-dependent metabolism | Yes |
| Estazolam | 1 to 2 | 2 (0.5 to 6) | 10 to 24 | $43 (18 to 27) for 1 mg nightly | Rapid onset, intermediate half-life; daytime sleepiness | Yes |
| Temazepam | 7.5 to 30 | 1.2 to 1.6 | 3.5 to 18.4 | $99 (20 to 21) for 15 mg | Medium onset, intermediate half-life; daytime sleepiness, less effective sleep induction | Yes |

**Herbs and supplements**

| Melatonin | 0.5 to 10 | 1 | 0.5 to 2 | $3 to 5 for 3 mg | Sleep disruption, daytime fatigue, headache, dizziness, irritability | No |
| Valerian root | 200 to 1,000 | 1 | Not known | $2 to 3 for 450 mg | Daytime sedation, hepatotoxicity | No |

**NOTE:** CNS stimulation includes insomnia, nervousness, euphoria, irritability, tremors, nightmares, hallucinations, and convulsions. CYP3A4 is antagonized or potentiated by inducers and inhibitors of the cytochrome P450 system, isoflavones 1α2, 2C9, 2D6, 3A (see http://www.medicine.iupui.edu/tobock/mlist.htm). FDA = U.S. Food and Drug Administration; CNS = central nervous system; SSRIs = selective serotonin reuptake inhibitors. *Prices for monthly starting doses. Estimated cost to the pharmacist based on average wholesale prices in Red Book, Montvale, N.J.: Medical Economics Data, 2007. Cost to the patient will be higher, depending on prescription filling fee. Prices are rounded to the nearest dollar. †Common adverse effects of nonbenzodiazepine hypnotics: headache, dizziness, and nausea; use caution with narcotics; additive effects with alcohol and CNS depressants. ‡Anticholinergic side effects: dry mouth, blurred vision, constipation, urinary retention, decreased sweating, increased heart rate, orthostatic hypotension, impaired concentration and memory, confusion, and delirium. §-Benzodiazepines: flurazepam (Dalmane) and quazepam (Doral) omitted because half-life > 24 hours; contraindicated in patients with narrow-angle glaucoma, untreated obstructive sleep apnea, history of substance abuse; adverse effects: drowsiness, dizziness, risk of falls and motor vehicle collisions, cognitive and functional decline, fatal overdose, tolerance, rebound insomnia. Reduce dosage in older adults; use caution with narcotics; additive effects with alcohol and CNS depressants. ||Generic temazepam not available as 7.5 mg.

weeks after discontinuing a long-acting benzodiazepine.23 Although often recommended, gradually tapering the dose alone is ineffective in achieving long-term discontinuation.34 However, combining CBT with tapering of benzodiazepines results in successful discontinuation in 70 percent of patients at 12 months.34

**NON-BENZODIAZEPINE HYPNOTICS**

The newer non-benzodiazepines selectively bind to type 1 benzodiazepine receptors in the CNS. Unlike benzodiazepines, the non-benzodiazepines have minimal impact on sleep stages and no REM sleep rebound. Tachyphylaxis is unusual. Non-benzodiazepines undergo hepatic degradation, and doses should be reduced in older patients and in those with hepatic dysfunction. Direct comparisons of non-benzodiazepines and benzodiazepines are not available. However, when indirectly compared, the non-benzodiazepines are similarly effective but have less overall risk of adverse effects.30 Nevertheless, these newer agents can cause impaired memory and psychomotor retardation.31 Non-benzodiazepine hypnotics approved by the FDA for the treatment of insomnia include zolpidem, zaleplon, and eszopiclone (Not available in RSA).

**Zolpidem**

Zolpidem decreases sleep-onset latency, improves sleep quality, increases stage 2 and slow-wave sleep, and does not exhibit tolerance or rebound following five weeks of continuous use at recommended dosages.42-46 Adverse effects occur at daily dosages of 20 mg or more. Because of its longer half-life, a controlled-release version in a dosage of 6.25 to 12.5 mg daily may be better for maintaining sleep, but it should not be re-administered following nocturnal awakenings and has not been shown to reduce adverse effects.17 Direct comparisons of zolpidem and controlled-release zolpidem have not been published.

**Zaleplon**

Zaleplon decreases sleep-onset latency. Its short half-life (i.e., one hour) enables re-administration following nocturnal awakenings. It is particularly useful in patients who have trouble falling asleep and maintaining sleep and can be administered up to four hours before the anticipated wake time.17 Zaleplon causes less memory and psychomotor impairment than do benzodiazepines and zolpidem.26 Some patients report visual disturbances, such as a change in color perception.

**Eszopiclone (Not available in RSA)**

Eszopiclone, an isomer of zopiclone, is the only hypnotic with FDA approval for use longer than 36 days. Eszopiclone has evidence of effectiveness for six months of therapy in a randomized, pla-
Table 7: Indirect Comparisons of the Effectiveness of Treatments for Insomnia

<table>
<thead>
<tr>
<th>Treatment</th>
<th>SOL (minutes)</th>
<th>WASO (minutes)</th>
<th>Sleep efficiency (%)</th>
<th>Total sleep time increase (minutes)</th>
<th>Sleep quality (SMD)</th>
<th>Risk difference†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-pharmacologic</td>
<td>-15.7 to -24</td>
<td>-22.5</td>
<td>-</td>
<td>24.3 to 32</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Relaxation§</td>
<td>-14.5</td>
<td>-1.6</td>
<td>0.4</td>
<td>23.0</td>
<td>0.37</td>
<td>-</td>
</tr>
<tr>
<td>Cognitive/behavioral§</td>
<td>-4.6</td>
<td>-18.2</td>
<td>5.5</td>
<td>0.7</td>
<td>0.38</td>
<td>-</td>
</tr>
<tr>
<td>Exercise§</td>
<td>-12</td>
<td>-</td>
<td>42</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Benzodiazepines§</td>
<td>-4.2 to -16.5</td>
<td>-23.1</td>
<td>6.3</td>
<td>39.1 to 61.8</td>
<td>0.06</td>
<td>0.15</td>
</tr>
<tr>
<td>Estazolam§</td>
<td>-10.2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Flurazepam§</td>
<td>-23.1</td>
<td>-12.4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Temazepam§</td>
<td>-11.6</td>
<td>-23.7</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Triazolam§</td>
<td>-19.7</td>
<td>-40.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Nonbenzodiazepines§</td>
<td>-18.1</td>
<td>-12.6</td>
<td>5.9</td>
<td>28.0</td>
<td>0.48</td>
<td>0.05</td>
</tr>
<tr>
<td>Eszopiclone§</td>
<td>-16.7</td>
<td>-25.8</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Zaleplon§</td>
<td>-20.1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Zolpidem§</td>
<td>-12.8</td>
<td>-8.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Antidepressants§</td>
<td>-7.4</td>
<td>-11.4</td>
<td>13.8</td>
<td>53.8</td>
<td>0.63</td>
<td>0.09</td>
</tr>
<tr>
<td>Doxepin§</td>
<td>-6.7</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Trazodone§</td>
<td>-12.2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Melatonin§</td>
<td>-8.3</td>
<td>-9.7</td>
<td>3.3</td>
<td>5.8</td>
<td>0.25</td>
<td>0.09</td>
</tr>
<tr>
<td>Valerian§</td>
<td>-1.3</td>
<td>-8.4</td>
<td>-0.1</td>
<td>0.8</td>
<td>1.38</td>
<td>0.06</td>
</tr>
</tbody>
</table>

SOL = sleep-onset latency, mean difference from placebo in minutes; WASO = wakefulness after sleep onset, mean difference from placebo in minutes; SMD = standardized mean difference from placebo-the greater the difference, the more effective the medication.

§Amount of time spent asleep as a percentage of total time spent in bed.
†Risk difference for adverse events. Risk difference is the increased risk of adverse events compared with placebo or no treatment.

Information from references 4, 13, 14, 16, and 22.

The abuse potential of hypnotics is often overstated. Most patients taking hypnotics do so for a short period; only 10 to 15 percent take hypnotics long-term. Although substance abusers may abuse benzodiazepines, they rarely abuse nonbenzodiazepines. Hypnotic overdose is generally not life-threatening unless more than one drug in a class of opiates are also ingested.

Table 7: Indirect Comparisons of the Effectiveness of Treatments for Insomnia

TREATMENT

A meta-analysis comparing pharmacologic and non-pharmacologic treatments found similar short-term effectiveness (two to four weeks) in patients with primary insomnia. Non-pharmacologic therapy showed slightly greater reductions in sleep-onset latency, but wakefulness after sleep onset, number of awakenings, total sleep time, and sleep quality were not significantly different. There are no direct comparisons of the effectiveness of the newer non-benzodiazepines and other medications for chronic insomnia. Indirect comparisons in which each medication was compared with placebo are shown in Table 7. In one meta-analysis, use of non-benzodiazepines did not significantly reduce sleep-onset latency compared with benzodiazepines; however, a significant reduction was noted when non-benzodiazepines were compared with antidepressant and melatonin therapies. Zolpidem and benzodiazepine therapies were equally effective compared with placebo for patients 65 years or younger. In a meta-analysis of patients 60 years and older with insomnia, researchers found that benzodiazepines and non-benzodiazepines were associated with an increased risk of adverse events.

The cost of non-benzodiazepines is considerably higher than benzodiazepines. An economic evaluation comparing the cost-effectiveness of non-pharmacologic treatment, benzodiazepines, eszopiclone, and no treatment in older adults found that, compared with benzodiazepines, non-pharmacologic therapy (i.e., CBT) produced a net gain of 0.37 quality-adjusted life-years at a savings of $2,781 over 10 years.

This is one in a series of "Clinical Pharmacology" articles coordinated by Allen F. Shaughnessy, PharmD, Tufts University Family Medicine Residency at Cambridge Health Alliance, Malden, Mass.
REFERENCES


